Immix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis
(RTTNews) - Tuesday, Immix Biopharma (IMMX) said an interim Phase 2 NEXICART-2 update showed an 89% complete response rate with investigational NXC-201 in relapsed/refractory AL amyloidosis.